|Articles|June 1, 2006

DRUG COMBO COULD HARM PATIENTS WITHOUT CLINICALLY EVIDENT CVD

A recent study of the safety and efficacyof clopidogrel (Plavix; 75 mg perday) plus aspirin (75-162 mg per day),compared with aspirin alone, resulted infindings that suggested no benefits andpossible harm from the combination ofthe 2 drugs. The study included 15,603patients with either clinically evidentcardiovascular disease (CVD) or multiplerisk factors for CVD. After a median of 28months of follow-up, the primary efficacyend point—a composite of myocardialinfarction (MI), stroke, or death fromcardiovascular causes—occurred inpatients with established CVD at ratesof 6.8% in the clopidogrel group and7.3% in the placebo group. In patientswith risk factors but no evidence of CVD,events occurred at rates of 6.6% in theclopidogrel group versus 5.5% in theplacebo group. Although this findingwas not statistically significant, therates of death between the 2 groupsdid reach statistically significant levels.Severe bleeding risks were elevatedin the combination group (1.7%vs 1.3%), as were the risks of moderatebleeding (2.1% vs 1.3%).

The American Heart Association hasissued a statement specifying thosepatients that may benefit from the useof clopidogrel. They include somepatients who have had an MI; patientswho have had angioplasty for unstableangina or heart attack; patients whohave received either a bare-metal ordrug-eluting stent; patients with peripheralartery disease; and patients whohave had a transient ischemic attack orother stroke.

Dr. Garrett is a clinical pharmacist practitionerat Cornerstone Health Care in HighPoint, NC.

Articles in this issue

over 19 years ago

Article

can you READ these Rxs?

over 19 years ago

Article

case STUDIES

over 19 years ago

Article

Compounding HOTLINE

over 19 years ago

Article

RESPy AWARD

over 19 years ago

Article

Compounding for Prenatal Patients

over 19 years ago

Article

Prescription Monitoring Programs

over 19 years ago

Article

FMEA Can Help Prevent Errors

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME